Basal Ganglia Pathophysiology
171 – 180 of 200
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
- Contribution to journal › Article
-
Mark
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
- Contribution to journal › Article
-
Mark
Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.
- Contribution to journal › Article
-
Mark
Chapte B7 - Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease
(2005) p.193-208
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2004
-
Mark
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
- Contribution to journal › Article
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
- Contribution to journal › Article
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
- Contribution to journal › Article
-
Mark
Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice
- Contribution to journal › Article
-
Mark
Genetic aspects of melatonin biology.
- Contribution to journal › Scientific review
-
Mark
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism
- Contribution to journal › Article
